Cargando…
Utilizing the MEST score for prognostic staging in IgA nephropathy
BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients wit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753851/ https://www.ncbi.nlm.nih.gov/pubmed/35016634 http://dx.doi.org/10.1186/s12882-021-02653-y |
_version_ | 1784632156482437120 |
---|---|
author | Haaskjold, Yngvar Lunde Bjørneklett, Rune Bostad, Leif Bostad, Lars Sigurd Lura, Njål Gjærde Knoop, Thomas |
author_facet | Haaskjold, Yngvar Lunde Bjørneklett, Rune Bostad, Leif Bostad, Lars Sigurd Lura, Njål Gjærde Knoop, Thomas |
author_sort | Haaskjold, Yngvar Lunde |
collection | PubMed |
description | BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients with biopsy-proven primary IgAN were included. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford classification. The study endpoint was end-stage renal disease (ESRD). Patients were subclassified into three risk models based on histologic features (Model A), a composite score calculated from the adjusted hazard ratio values (Model B), and on quartiles (Model C). RESULTS: The mean follow-up time was 16.5 years (range 0.2–28.1). In total, 61 (20%) patients reached ESRD during the study period. Univariate analysis of M, E, S, T and C lesions demonstrated that all types were associated with an increased risk of ESRD; however, a multivariate analysis revealed that only S, T and C lesions were associated with poor outcomes. Statistical analysis of 15-year data demonstrated that Models A and B were as predictive as the MEST score, with an area-under-the-curve at 0.85. The Harrel c index values were 0.81 and 0.80 for the MEST score and Models A and B, respectively. In the present cohort, adding C lesions to the MEST score did not improve the models prognostic value. CONCLUSIONS: Patients can be divided into risk classes based on their MEST scores. Histopathologic data provide valuable prognostic information at the time of diagnosis. Model B was the most suitable for clinical practice because it was the most user-friendly. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02653-y. |
format | Online Article Text |
id | pubmed-8753851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87538512022-01-12 Utilizing the MEST score for prognostic staging in IgA nephropathy Haaskjold, Yngvar Lunde Bjørneklett, Rune Bostad, Leif Bostad, Lars Sigurd Lura, Njål Gjærde Knoop, Thomas BMC Nephrol Research BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients with biopsy-proven primary IgAN were included. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford classification. The study endpoint was end-stage renal disease (ESRD). Patients were subclassified into three risk models based on histologic features (Model A), a composite score calculated from the adjusted hazard ratio values (Model B), and on quartiles (Model C). RESULTS: The mean follow-up time was 16.5 years (range 0.2–28.1). In total, 61 (20%) patients reached ESRD during the study period. Univariate analysis of M, E, S, T and C lesions demonstrated that all types were associated with an increased risk of ESRD; however, a multivariate analysis revealed that only S, T and C lesions were associated with poor outcomes. Statistical analysis of 15-year data demonstrated that Models A and B were as predictive as the MEST score, with an area-under-the-curve at 0.85. The Harrel c index values were 0.81 and 0.80 for the MEST score and Models A and B, respectively. In the present cohort, adding C lesions to the MEST score did not improve the models prognostic value. CONCLUSIONS: Patients can be divided into risk classes based on their MEST scores. Histopathologic data provide valuable prognostic information at the time of diagnosis. Model B was the most suitable for clinical practice because it was the most user-friendly. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02653-y. BioMed Central 2022-01-11 /pmc/articles/PMC8753851/ /pubmed/35016634 http://dx.doi.org/10.1186/s12882-021-02653-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Haaskjold, Yngvar Lunde Bjørneklett, Rune Bostad, Leif Bostad, Lars Sigurd Lura, Njål Gjærde Knoop, Thomas Utilizing the MEST score for prognostic staging in IgA nephropathy |
title | Utilizing the MEST score for prognostic staging in IgA nephropathy |
title_full | Utilizing the MEST score for prognostic staging in IgA nephropathy |
title_fullStr | Utilizing the MEST score for prognostic staging in IgA nephropathy |
title_full_unstemmed | Utilizing the MEST score for prognostic staging in IgA nephropathy |
title_short | Utilizing the MEST score for prognostic staging in IgA nephropathy |
title_sort | utilizing the mest score for prognostic staging in iga nephropathy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753851/ https://www.ncbi.nlm.nih.gov/pubmed/35016634 http://dx.doi.org/10.1186/s12882-021-02653-y |
work_keys_str_mv | AT haaskjoldyngvarlunde utilizingthemestscoreforprognosticstaginginiganephropathy AT bjørneklettrune utilizingthemestscoreforprognosticstaginginiganephropathy AT bostadleif utilizingthemestscoreforprognosticstaginginiganephropathy AT bostadlarssigurd utilizingthemestscoreforprognosticstaginginiganephropathy AT luranjalgjærde utilizingthemestscoreforprognosticstaginginiganephropathy AT knoopthomas utilizingthemestscoreforprognosticstaginginiganephropathy |